Tandem Diabetes Care (NASDAQ: TNDM) revenue
Tandem Diabetes Care reported revenue of $1,015m for fiscal 2025, 7.9% more than in fiscal 2024 ($940.2m). Since fiscal 2016 its revenue has grown by 1,104.5%, an average growth of 31.9% a year.
Tandem Diabetes Care has grown its revenue for 2 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2023, −6.7%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,015m | +7.9% | −$187.3m | −18.5% |
| 2024 | $940.2m | +25.7% | −$99.1m | −10.5% |
| 2023 | $747.7m | −6.7% | −$233.2m | −31.2% |
| 2022 | $801.2m | +14.0% | −$92.8m | −11.6% |
| 2021 | $702.8m | +40.9% | $22.7m | 3.2% |
| 2020 | $498.8m | +37.7% | −$8.0m | −1.6% |
| 2019 | $362.3m | +97.0% | −$16.7m | −4.6% |
| 2018 | $183.9m | +70.9% | −$44.6m | −24.3% |
| 2017 | $107.6m | +27.7% | −$62.9m | −58.5% |
| 2016 | $84.2m | — | −$78.1m | −92.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Tandem Diabetes Care revenue compared with its sector
By revenue for its latest fiscal year, Tandem Diabetes Care ranks 148th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Tandem Diabetes Care, 7.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 146th | Embecta | $1,080m | −3.8% |
| 147th | Acadia Pharmaceuticals | $1,072m | 11.9% |
| 148th | Tandem Diabetes Care | $1,015m | 7.9% |
| 149th | InnovAge | $989.7m | 15.9% |
| 150th | Guardant Health | $982.0m | 32.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Tandem Diabetes Care
- How much revenue did Tandem Diabetes Care make in fiscal 2025?
- Tandem Diabetes Care reported revenue of $1,015m for fiscal 2025, compared with $940.2m in fiscal 2024.
- How much has the revenue of Tandem Diabetes Care grown?
- Between fiscal 2016 and fiscal 2025 it went from $84.2m to $1,015m: 1,104.5% more, an average growth of 31.9% a year.
- What was the best year for revenue at Tandem Diabetes Care?
- Of its last 10 fiscal years, fiscal 2025, with $1,015m.
- Where does Tandem Diabetes Care rank in its sector by revenue?
- It ranks 148th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Tandem Diabetes Care come from?
- From the annual report (Form 10-K) that Tandem Diabetes Care files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Tandem Diabetes Care files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Tandem Diabetes Care: the Tandem Diabetes Care page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.